AwardJul 26, 2026, 07:35 PM
Ascentage Pharma CEO Dr. Dajun Yang Named to Medicine Maker Power List
AI Summary
Ascentage Pharma announced that its Chairman and CEO, Dr. Dajun Yang, has been named to The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. This recognition highlights his over 30 years of work in oncology and innovative drug development, leading Ascentage Pharma to commercialize two therapies, olverembatinib and lisaftoclax, and advance multiple global Phase III clinical studies. The company also achieved dual primary listings under his leadership.
Key Highlights
- Dr. Dajun Yang ranked No. 3 in the Small Molecules category of The Medicine Maker Power List 2026.
- Olverembatinib was the first third-generation BCR-ABL tyrosine kinase inhibitor approved in China.
- Lisaftoclax was the second Bcl-2 inhibitor approved globally since venetoclax in 2016.
- Ascentage Pharma has successfully commercialized two innovative therapies: olverembatinib and lisaftoclax.
- The company is advancing multiple global registrational Phase III clinical studies, four cleared by FDA and EMA.
- Lisaftoclax is the only Bcl-2 inhibitor in global registrational Phase III for higher-risk MDS.
- Ascentage Pharma achieved dual primary listings on the Hong Kong Stock Exchange and Nasdaq.
Price Impact
More from AAPG